Mumbai: Pharmaceutical majors Cipla and Roche Products India said on Thursday they have entered into an agreement to provide better access to innovative medicines for patients in India.
Under the agreement, Cipla will be responsible for the marketing and distribution of Roche Pharma's key trademark oncology drugs Trastuzumab (Herclon), Bevacizumab (Avastin) and Rituximab (Ristova).
Roche and Cipla had previously entered into a similar agreement in February 2018 for the promotion and distribution of Tocilizumab (Actemra) and other products.